Massachusetts is currently home to 3159 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Abbott Ventricular Tachycardia PAS
NCT05839873
Recruiting
This post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment. This is a prospective, single arm, open-label, multi-center, observational study.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Ventricular Tachycardia
Register for Updates
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
NCT05776277
Recruiting
This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Fecal Incontinence
Register for Updates
A Mobile Gaming App to Improve Adherence to PrEP
NCT05762705
Recruiting
In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi. Formative evaluation interviews will be conducted with stakeholders (healthcare workers, clinic administrators, and patients taking PrEP) to inform intervention delivery. Data from the formative interviews will also be used to make necessary adaptations to the game and assess... Read More
Gender:
ALL
Ages:
Between 15 years and 34 years
Trial Updated:
04/02/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Medication Adherence, HIV/AIDS
Register for Updates
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
NCT05605093
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital (202-002), Boston, Massachusetts
Conditions: COVID-19
Register for Updates
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
NCT05517421
Recruiting
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Site Number - 1506, Boston, Massachusetts
Conditions: Thyroid Eye Disease
Register for Updates
EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA
NCT05480228
Recruiting
The purpose of this study is to investigate the safety and efficacy of the current hard gelatin capsule formulation of NRD135S.E1 80 mg once daily in the treatment of PDPN when administered for 13 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: MGH Department of Anesthesia, Critical Care, and Pain, Boston, Massachusetts
Conditions: Painful Diabetic Neuropathy
Register for Updates
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903
Recruiting
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
NCT05361070
Recruiting
The NSR-GENE study is a longitudinal cohort study of approximately 300 parent-child trios from the Neonatal Seizure Registry and participating site outpatient clinics that aims to evaluate whether and how genes alter the risk of post-neonatal epilepsy among children with acute provoked neonatal seizures. The researchers aim to develop prediction rules to stratify neonates into low, medium, and high risk for post-neonatal epilepsy based on clinical, electroencephalogram (EEG), magnetic resonance... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhage, Epilepsy, Gene Abnormality
Register for Updates
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973
Recruiting
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethni... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Amyloidosis
Register for Updates
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916
Recruiting
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third o... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Genesis Clinical Research - Fall River- Site Number : 8400050, Fall River, Massachusetts
Conditions: Asthma
Register for Updates
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089
Recruiting
The SYN 20-01 Study is a non-interventional, prospective, multicenter, multicohort, international, post-market clinical investigation looking into the assessment of GORE® SYNECOR Biomaterial in focused patient populations and in long-term application. Patients with ventral / incisional hernia amenable to hernia mesh repair will be enrolled into two cohorts (US and EU cohort) and followed-up over the period of 60 months.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
Register for Updates